Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: Potential for consolidation in ovarian cancer

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 2, 2011, Pages 457-463

  Andreopoulou, Eleni ^a   Chen, Thomas ^b   Liebes, Leonard ^c   Curtin, John ^c   Blank, Stephanie ^c   Wallach, Robert ^c   Hochster, Howard ^d   Muggia, Franco ^c  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b BANNER HEALTH   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d YALE CANCER CENTER   (United States)

Author keywords

Cisplatin; Intraperitoneal; Ovarian cancer; Topotecan

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; FLOXURIDINE; LOPERAMIDE; PACLITAXEL; PLATINUM COMPLEX; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; TAXANE DERIVATIVE; TOPOTECAN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTRECTOMY; HUMAN; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PERITONITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STAPHYLOCOCCUS EPIDERMIDIS; STOMACH CANCER; THROMBOCYTOPENIA; TUBOOVARIAN CANCER; UNSPECIFIED SIDE EFFECT; URTICARIA; UTERINE TUBE TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITIC FLUID; CISPLATIN; COHORT STUDIES; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; INFUSIONS, PARENTERAL; LACTONES; MIDDLE AGED; NEUTROPENIA; OVARIAN NEOPLASMS; REMISSION INDUCTION; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TOPOISOMERASE I INHIBITORS; TOPOTECAN;

EID: 79960913163     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1510-y     Document Type: Article

References (38)

1. RL Dedrick CE Myers PM Bungay VT DeVita Jr 1978 Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer Cancer Treat Rep 62 1 1 11 626987 1:CAS:528:DyaE1cXhsVGqs78%3D (Pubitemid 8278518)
2. SB Howell CE Pfeifle We Wung RA Olshen 1983 Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection Cancer Res 43 3 1426 1431 6681730 1:STN:280:DyaL3s7ivFSqtw%3D%3D (Pubitemid 13160080)
3. JS Berek M Markman B Stonebraker, et al. 1999 Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study Gynecol Oncol 75 1 10 14 10502418 10.1006/gyno.1999.5532 1:CAS:528:DyaK1MXmt1WqtL0%3D (Pubitemid 29477794)
4. RJ Morgan Jr K Margolin J Raschko, et al. 1995 Phase I trial of carboplatin and infusional cyclosporin in advanced malignancy J Clin Oncol 13 9 2238 2246 7666081 1:CAS:528:DyaK2MXoslaqtLg%3D
5. RJ Morgan Jr TW Synold B Xi, et al. 2007 Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity Clin Cancer Res 13 1232 1237 17317834 10.1158/1078-0432.CCR- 06-1735 1:CAS:528:DC%2BD2sXhvF2hsbY%3D (Pubitemid 46437052)
6. RJ Morgan Jr JH Doroshow T Synold, et al. 2003 Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics Clin Cancer Res 9 16 Pt 1 5896 5901 14676112 1:CAS:528:DC%2BD3sXpsl2ls74%3D (Pubitemid 38018073)
7. Choi MK, Ahn BJ, Yim DS et al (2010) Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding. Cancer Chemother Pharmacol Mar 6 [Epub ahead of print]
8. RF Ozols 1992 Intraperitoneal salvage chemotherapy in ovarian cancer: who is left to treat? Gynecol Oncol 45 1 1 2 1601329 10.1016/0090-8258(92)90481-W 1:STN:280:DyaK383ptVeitQ%3D%3D
9. FM Muggia DS Alberts 1991 Intraperitoneal therapy in ovarian cancer: time's not up (letter) J Clin Oncol 9 8 1510 1516 2072150 1:STN:280: DyaK3MzgtlajtQ%3D%3D
10. FM Muggia 1992 More on intraperitoneal therapy (letter) Ann Oncol 3 492 1307863 1:STN:280:DyaK38zmtVGgsQ%3D%3D
11. NCI Clinical Alert on Intraperitoneal Therapy of Ovarian Cancer (2006) Jan 4
12. DS Alberts PY Liu EV Hannigan, et al. 1996 Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N Engl J Med 335 26 1950 1955 8960474 10.1056/NEJM199612263352603 1:CAS:528:DyaK2sXivVajtA%3D%3D (Pubitemid 26428219)
13. DK Armstrong B Bundy L Wenzel, et al. 2006 Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 1 34 43 16394300 10.1056/NEJMoa052985 1:CAS:528:DC%2BD28XhvV2qsQ%3D%3D (Pubitemid 43048949)
14. M Markman BN Bundy DS Alberts, et al. 2001 Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group J Clin Oncol 19 1001 1007 11181662 1:CAS:528: DC%2BD3MXhvFersbg%3D (Pubitemid 32176274)
15. Jaaback K, Johnson N (2006) Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev (1):CD005340
16. L Elit TK Oliver A Covens J Kwon MF Fung HW Hirte AM Oza 2007 Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses Cancer 109 4 692 702 17238181 10.1002/cncr.22466 1:CAS:528:DC%2BD2sXis1Smt78%3D (Pubitemid 46233230)
17. United States National Library of Medicine, National Institutes of Health (2005) NCI Issues Clinical Announcement for preferred method of treatment for Advanced Ovarian Cancer. http://www.nlm.nih.gov/databases/alerts/ovarian-ip- chemo.html accessed Jan 2010
18. M Piccart A Floquet G Scarfone, et al. 2003 Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized Phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy Int J Gynecol Cancer 13 suppl 2 196 203 14656280 10.1111/j.1525-1438.2003.13360.x (Pubitemid 38228765)
19. WP McGuire 2009 Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates J Clin Oncol 27 4633 4634 19704055 10.1200/JCO.2009.23.6653
20. FM Muggia PY Liu DS Alberts, et al. 1996 Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy Gynecol Oncol 61 395 402 8641622 10.1006/gyno.1996.0163 1:CAS:528:DyaK28XjvVyrsbc%3D
21. FM Muggia S Groshen C Russell, et al. 1993 Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimens Gynecol Oncol 50 232 238 8375739 10.1006/gyno.1993.1198 1:STN:280:DyaK3szoslOqsg%3D%3D (Pubitemid 23275210)
22. RR Barakat P Sabbatini D Bhaskaran, et al. 2002 Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow up J Clin Oncol 20 694 698 11821450 10.1200/JCO.20.3.694 (Pubitemid 34111376)
23. MJ Lu J Sorich M Hazarika, et al. 2003 Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy Hematol Oncol Clin North Am 17 4 969 975 12959186 10.1016/S0889-8588(03)00059-5 (Pubitemid 37022152)
24. F Muggia S Jeffers L Muderspach, et al. 1997 Phase I/II study of intraperitoneal floxuridine and platinum (cisplatin and/or carboplatin) Gynecol Oncol 66 2 290 294 9264578 10.1006/gyno.1997.4778 1:CAS:528:DyaK2sXlsV2nsbs%3D (Pubitemid 27335419)
25. J Menczer G Ben-Baruch S Rizel H Brenner 1992 Intraperitoneal cisplatin chemotherapy in ovarian carcinoma patients who are clinically in complete remission Gynecol Oncol 46 2 222 225 1500025 10.1016/0090-8258(92)90259-L 1:STN:280:DyaK38zmtlaqsA%3D%3D
26. A De Gramont B Demuynck C Louvet, et al. 1992 Survival with intraperitoneal cisplatin in advanced ovarian cancer after second look laparotomy Am J Clin Oncol 15 1 7 11 1550083 10.1097/00000421-199202000-00002
27. HM Tarraza Jr CR Boyce WG Smith, et al. 1993 Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second look laparotomy Gynecol Oncol 50 3 287 290 8406188 10.1006/gyno.1993.1212 (Pubitemid 23299720)
28. RR Barakat L Almadrones ES Venkatraman, et al. 1998 A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment Gynecol Oncol 69 1 17 22 9570993 10.1006/gyno.1998.4973 1:CAS:528:DyaK1cXjtVGltLc%3D (Pubitemid 28201666)
29. ML Rothenberg PY Liu PS Braly, et al. 2003 Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial J Clin Oncol 21 7 1313 1319 12663720 10.1200/JCO.2003.07.031 1:CAS:528:DC%2BD2cXpsVWqsLY%3D (Pubitemid 46606409)
30. F Muggia L Liebes M Potmesil, et al. 2000 Intraperitoneal topoisomerase-I inhibitors: preliminary findings with 9-aminocamptothecin Ann N Y Acad Sci 922 178 187 11193893 10.1111/j.1749-6632.2000.tb07036.x 1:CAS:528: DC%2BD3MXntVCrsw%3D%3D (Pubitemid 32050252)
31. EK Rowinsky SH Kaufman SD Baker, et al. 1996 Sequences of topotecan and cisplatin: phase I pharmacologic and in vitro studies to examine sequence dependence J Clin Oncol 14 3074 3084 8955652 1:CAS:528:DyaK2sXitl2isg%3D%3D (Pubitemid 26408800)
32. H Hochster L Liebes J Speyer, et al. 1997 Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study Clin Can Res 3 1245 1252 1:CAS:528:DyaK2sXls1Smtr4%3D (Pubitemid 27362384)
33. LS Hofstra AM Bos EG de Vries, et al. 2001 A phase I and pharmacokinetic study of intraperitoneal topotecan Br J Cancer 85 11 1627 1633 11742479 10.1054/bjoc.2001.2161 1:CAS:528:DC%2BD38XnsVCiug%3D%3D (Pubitemid 34081504)
34. SC Plaxe RD Christen J O'Quigley, et al. 1998 Phase I and pharmacokinetic study of intraperitoneal topotecan Invest New Drugs 16 147 153 9848578 10.1023/A:1006045125018 1:CAS:528:DyaK1cXnvVOlsr8%3D (Pubitemid 28495216)
35. Muntz HG, Malpass TW, McGonigle KG et al (2008) Phase II study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal cancer. Cancer 113:490-496
36. S De Placido G Scambia G Di Vagno, et al. 2004 Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study J Clin Oncol 22 2635 2642 15226331 10.1200/JCO.2004.09.088 (Pubitemid 41103751)
37. J Pfisterer B Weber A Reuss, et al. 2006 Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO J Natl Cancer Inst 98 1036 1045 16882940 10.1093/jnci/djj296 1:CAS:528:DC%2BD28XoslWltLc%3D (Pubitemid 44288151)
38. DK Shah BS Shin J Veith K Tóth RJ Bernacki JP Balthasar 2009 Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy J Pharmacol Exp Ther 329 580 591 19233938 10.1124/jpet.108.149443 1:CAS:528: DC%2BD1MXlt1Olsr0%3D